ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026, for Outlook Therapeutics’ ...
Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...
NEW ORLEANS -- Two poster sessions that spanned 4 days of the American Academy of Ophthalmology meeting provided new data about the natural history and management of age-related macular degeneration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results